Download PDF
Semin Neurol 2001; 21(1): 059-068
DOI: 10.1055/s-2001-13120
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Movement Disorders Induced by Dopamine Blocking Agents

Kapil D. Sethi
  • Medical College of Georgia, Augusta, Georgia
Further Information

Publication History

Publication Date:
31 December 2001 (online)

    Permissions and Reprints

ABSTRACT

Movement disorders are frequently due to dopamine blocking agents (DBAs) prescribed for psychiatric illnesses. DBAs are sometimes also prescribed inappropriately for other maladies. These drugs can cause a wide variety of involuntary movements, sometimes in combination. When these appear in the setting of psychiatric illnesses, the association is easy to recognize but the treatment remains a difficult problem. However, in other situations the diagnosis may be missed for extended periods of time, resulting in unnecessary diagnostic work-up and inappropriate therapy. The diagnosis depends on a compulsive drug history not only from the patient but also from patient's family, primary physician, and the pharmacist. The treatment options include removal of the offending agent or substitution with an atypical neuroleptic. Symptomatic treatments are varied and have an inconsistent effect on the movement disorders. Prevention remains the most important strategy.

KEYWORD

Tardive dyskinesia - antipsychotic drugs - schizophrenia - risk factors - pathophysiology - treatment - drug-induced parkinsonism - dopamine blocking agents

REFERENCES

  • 1 Delay J, Deniker P. Chlorpromazine and neuroleptic treatment in psychiatry.  J Clin Exp Psychopathol . 1956;  17 19-24
    PubMedGoogle Scholar
  • 2 Uhrbrand L, Faurbye A. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy.  Psychopharmacology (Berl) . 1960;  1 408-418
    CrossrefPubMedGoogle Scholar
  • 3 Tolosa E, Alom J, Marti M J. Drug-induced dyskinesias. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders 2nd ed. Baltimore: Williams & Wilkins 1993: 375-397
    Google Scholar
  • 4 Ekbom K, Lindholm H, Ljungberg L. New dystonic syndrome associated with butyrophenone therapy.  Z Neurol . 1972;  202 94-103
    CrossrefPubMedGoogle Scholar
  • 5 Suzuki T, Koizumi J, Moroji T. Clinical characteristics of the Pisa syndrome.  Acta Psychiatr Scand . 1990;  82 454-457
    PubMedGoogle Scholar
  • 6 Nealer R, Gerhardt S, Liebman J M. Effects of dopamine agonists, catecholamine depletors, and cholinergic and GABAergic drugs on acute dyskinesia in the squirrel monkeys.  Psychopharmacology (Berl). 1984;  82 20-26
    PubMedGoogle Scholar
  • 7 Marsden C D, Jenner P. The pathophysiology of extrapyramidal side effects of neuroleptic drugs.  Psychol Med . 1980;  10 55-72
    PubMedGoogle Scholar
  • 8 Hardie R J, Lees A J. Neuroleptic induced Parkinson's syndrome: clinical features and results of treatment with levodopa.  Neurology . 1987;  37 850-854
    PubMedGoogle Scholar
  • 9 Stephen P J, Williamson J. Drug-induced parkinsonism in the elderly.  Lancet . 1984;  2 1082-1083
    PubMedGoogle Scholar
  • 10 Masso J F, Poza J J. Druginduced or aggravated parkinsonism: clinical signs and the changing pattern of implicated drugs.  Neurologia . 1996;  11 10-15
    PubMedGoogle Scholar
  • 11 Mutch W J, Dingwall-Fordyce I, Downie A W. Parkinson's disease in a Scottish city.  Br Med J . 1986;  292 534-536
    CrossrefPubMedGoogle Scholar
  • 12 Sethi K D, Patel B, Meador K J. Metoclopramide-induced parkinsonism.  South Med J . 1989;  82 1581-1582
    PubMedGoogle Scholar
  • 13 Korczyn A D, Goldberg G J. Extrapyramidal effects of neuroleptics.  J Neurol Neurosurgery Psychiatry . 1976;  39 866-869
    PubMedGoogle Scholar
  • 14 Gartmann J, Hartmann K, Kuhn M. Sanz-Streitlicht Nr 14.  Schweiz Arzt Ztg . 1993;  29 1163-1164
    PubMedGoogle Scholar
  • 15 Sethi K D, Zamrini E Y. Asymmetry in clinical features of drug-induced parkinsonism.  J Neuropsychiatry Clin Neurosci . 1990;  2 64-66
    PubMedGoogle Scholar
  • 16 Giladi N, Kao R, Fahn S. Freezing phenomenon in patients with parkinsonian syndromes.  Mov Disord . 1997;  12 302-305
    CrossrefPubMedGoogle Scholar
  • 17 Decina P, Caracci G, Scapichio P L. The rabbit syndrome.  Mov Disord . 1990;  5 263-266
    CrossrefPubMedGoogle Scholar
  • 18 Farde L, Wiesel F A, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.  Arch Gen Psychiatry . 1988;  45 71-76
    CrossrefPubMedGoogle Scholar
  • 19 Bunney B S. Antipsychotic drug effects on the electrical activity of dopaminergic neurones.  Trends Neurosci . 1984;  7 212-215
    CrossrefPubMedGoogle Scholar
  • 20 Casey D. Neuroleptic induced acute extrapyramidal syndromes and tardive dyskinesia.  Psychiatr Clin North Am . 1993;  16 589-610
    PubMedGoogle Scholar
  • 21 Reches A, Burke R E, Kuker C M. Tetrabenazine, an awine-depleting drug, also block dopamine receptors.  J Pharmacol Exp Ther . 1983;  225 515-521
    PubMedGoogle Scholar
  • 22 Goetz C G. Drug-induced parkinsonism and idiopathic Parkinson's disease.  Arch Neurol . 1983;  40 325-326
    PubMedGoogle Scholar
  • 23 Marti Masso F J, Carrera N, Urtasun M. Drugs inducing parkinsonism in our environment [abstract].  J Neurol Neurosurg Psychiatry . 1991;  54 1025
    PubMedGoogle Scholar
  • 24 Rajput A H, Rozdilsky B, Hornykiewikcz O. Reversible drug-induced parkinsonism: clinicopathologic study of two cases.  Arch Neurol . 1982;  39 644-646
    PubMedGoogle Scholar
  • 25 Klawans H L, Bergan D, Bruyn G W. Prolonged drug induced parkinsonism.  Confin Neurol . 1973;  35 368-377
    PubMedGoogle Scholar
  • 26 Burn D J, Brooks D J. Nigral dysfunction in drug-induced parkinsonism: an 18fluorodopa PET study.  Neurology . 1993;  43 552-556
    PubMedGoogle Scholar
  • 27 Kelly J T, Zimmerman R L, Abuzzahab F S, Schiele B C. A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug induced parkinsonism.  Pharmacology . 1974;  12 65-73
    PubMedGoogle Scholar
  • 28 Fann W E, Lake C R. Amantadine versus trihexyphenidyl in the treatment of neuroleptic induced parkinsonism.  Am J Psychiatry . 1976;  133 940-943
    PubMedGoogle Scholar
  • 29 Shoulson I. Carbidopa/levodopa therapy of coexisting drug induced parkinsonism and tardive dyskinesia.  Adv Neurol . 1983;  37 259-265
    PubMedGoogle Scholar
  • 30 Adler L A, Angrist B, Rotrosen J. Acute neuroleptic-induced akathisia. In: Lang AE, Weiner W, eds. Drug-Induced Movement Disorders Mount Kisco, NY: Futura Publishing Co 1992: 85-119
    Google Scholar
  • 31 Barnes T RE, Brando W M. Akathisia variants and tardive dyskinesia.  Arch Gen Psychiatry . 1985;  42 874-878
    PubMedGoogle Scholar
  • 32 Nordstrom A L, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol.  Psychopharmacology (Berl) . 1992;  106 433-438
    PubMedGoogle Scholar
  • 33 Farde L, Nordstrom A, Weisel F. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine.  Arch Gen Psychiatry . 1992;  49 539-544
    PubMedGoogle Scholar
  • 34 Baldessarini R J, Cole J O, Davis J M. Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association.  Am J Psychiatry . 1980;  137 1163-1172
    PubMedGoogle Scholar
  • 35 Jeste D V, Lacro J P, Palmer B. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients.  Am J Psychiatry . 1999;  156 309-311
    PubMedGoogle Scholar
  • 36 Fenn D S, Moussaoui D, Hoffman W F. Movements in nevermedicated schizophrenics: a preliminary study.  Psychopharmacology (Berl) . 1996;  123 206-210
    PubMedGoogle Scholar
  • 37 Marsden C D. Is tardive dyskinesia a unique disorder?. In: Casey DE, ed. Dyskinesia Research and Treatment Psychopharm Suppl 2. Berlin: Springer-Verlag 1985: 64-71
    Google Scholar
  • 38 Khot V, Wyatt R J. Not all that moves is tardive dyskinesia.  Am J Psychiatry . 1991;  148 661-666
    PubMedGoogle Scholar
  • 39 Jeste D V, Caligiuri M P. Tardive dyskinesia (review).  Schizophr Bull . 1993;  19 303-315
    CrossrefPubMedGoogle Scholar
  • 40 Gold J M, Egan M F, Kirch D G. Tardive dyskinesia: neuropsychological, computerized tomographic, and psychiatric symptom findings.  Biol Psychiatry . 1991;  30 587-599
    CrossrefPubMedGoogle Scholar
  • 41 Mion C C, Andreasen N C, Arndt S, Swayze II W V, Cohen G A. MRI abnormalities in tardive dyskinesia.  Psychiatry Res . 1991;  40 157-166
    CrossrefPubMedGoogle Scholar
  • 42 Steen V M, Lovlie R, MacEwan T, McCreadie R G. Dopamine D3receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients.  Mol Psychiatry . 1997;  2 86-88
    CrossrefPubMedGoogle Scholar
  • 43 Jankovic J. Tardive syndromes and other drug induced movement disorders.  Clin Neuropharmacol . 1995;  18 197-214
    CrossrefPubMedGoogle Scholar
  • 44 Weiner W J, Goetz C G, Paul A N, Klawans H L. Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea.  Ann Intern Med . 1978;  88 327-331
    PubMedGoogle Scholar
  • 45 Gardos G, Cole J O, Tarsy D. Withdrawal syndromes associated with antipsychotic drugs.  Am J Psychiatry . 1978;  135 1321-1324
    PubMedGoogle Scholar
  • 46 Gardos G, Cole J O. Overview: public health issues in tardive dyskinesia.  Am J Psychiatry . 1980;  137 776-781
    PubMedGoogle Scholar
  • 47 Hitri A, Weiner W, Borison R. Dopamine binding following prolonged haloperidol pretreatment.  Ann Neurol . 1978;  3 134-140
    CrossrefPubMedGoogle Scholar
  • 48 Jeste D V, Wyatt R J. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity?.  J Clin Psychiatry . 1981;  42 455-457
    PubMedGoogle Scholar
  • 49 May Reynolds P G, Brown J E, McCall J C, Mackay A V. Dopamine receptor abnormalities in the striatum and pallidum in tardive dyskinesia: a postmortem study.  J Neural Transm Gen Sect . 1992;  87 225-230
    CrossrefPubMedGoogle Scholar
  • 50 Anderson U, Eckernas S A, Harting P. Striatalbinding of 11C-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: no evidence for altered dopamine D2 receptor binding.  J Neural Transm Gen Sect . 1990;  79 215-226
    CrossrefPubMedGoogle Scholar
  • 51 Pahl J J, Mazziotta J C, Bartzokis G. Positron-emission tomography in tardive dyskinesia.  J Neuropsychiatry Clin Neurosci . 1995;  7 457-465
    PubMedGoogle Scholar
  • 52 Jankovic J, Beach J. Longterm effects of tetrabenazine in hyperkinetic movement disorders.  Neurology . 1997;  48 358-362
    PubMedGoogle Scholar
  • 53 Fahn S. Long term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.  Adv Neurol . 1983;  37 267-276
    PubMedGoogle Scholar
  • 54 Klawans H L, Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia.  J Neurol Neurosurg Psychiatry . 1974;  27 941-947
    PubMedGoogle Scholar
  • 55 Tamminga C A, Crayton J, Chase T. Improvement in tardive dyskinesia after muscimol therapy.  Arch Gen Psychiatry . 1979;  36 595-598
    PubMedGoogle Scholar
  • 56 Lieberman J A, Alvin J, Mukherjee S, Kane J M. Treatment of tardive dyskinesia with bromocriptine: a test of the receptor modification strategy.  Arch Gen Psychiatry . 1989;  46 908-913
    PubMedGoogle Scholar
  • 57 Stewart R M, Rollins J, Beckham B, Roffman M. Baclofen in tardive dyskinesia patients maintained on neuroleptics.  Clin Neuropharmacol . 1982;  5 365-373
    PubMedGoogle Scholar
  • 58 Thaker G K, Nguyen J A, Strauss M E. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy.  Am J Psychiatry . 1990;  147 445-451
    PubMedGoogle Scholar
  • 59 Duncan E, Adler L, Angrist B, Rotrosen J. Nifedipine in the treatment of tardivedyskinesia.  J Clin Pharmacol . 1990;  10 414-416
    PubMedGoogle Scholar
  • 60 Loonen A J, Verwey H A, Roels P R, Van Bavel P L, Doorschot C H. Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients?.  J Clin Psychopharmacol . 1992;  12 39-42
    PubMedGoogle Scholar
  • 61 Elkashef A M, Ruskin P E, Bacher N, Barrett D. Vitamin E in the treatment of tardive dyskinesia.  Am J Psychiatry . 1990;  147 4:505-506
    PubMedGoogle Scholar
  • 62 Lohr J B, Caligiuri M P. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.  J Clin Psychiatry . 1996;  57 167-173
    PubMedGoogle Scholar
  • 63 Shiriqui C L, Bradwejn J, Annable L, Jones B D. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study.  Am J Psychiatry . 1992;  149 391-393
    PubMedGoogle Scholar
  • 64 Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian Multicenter Risperidone Study.  J Clin Psychopharmacol . 1995;  36S-44S (36S-44S)
    PubMedGoogle Scholar
  • 65 Gwinn K A, Caviness J N. Risperidoneinduced tardive dyskinesia and parkinsonism.  Mov Disord . 1997;  12 119-121
    PubMedGoogle Scholar
  • 66 Anand V S, Dewan M J. Withdrawalemergent dyskinesia in a patient on risperidone undergoing dosage reduction.  Ann Clin Psychiatry . 1996;  8 179-182
    PubMedGoogle Scholar
  • 67 Burke R E, Kang U J, Jankovic J, Miller L G, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials.  Mov Disord . 1989;  4 157-175
    CrossrefPubMedGoogle Scholar
  • 68 Schilkurt V R, Duran E, Haverbeck C, Katz I, Vidal P. Verlauf von psychopathologischen und extrapyramidalmotorischen symptomen unter einer Langzeit-Neuroleptika behandlung schizophrener Patienten.  Drug Res . 1978;  28 1484-1495
    PubMedGoogle Scholar
  • 69 Lang A E. Withdrawal akathisia: case reports and a proposed classification of chronic akathisia.  Mov Disord . 1994;  9 188-192
    CrossrefPubMedGoogle Scholar
  • 70 Burke R E, Fahn S, Jankovic J. Tardive dystonia: late onset and persistent dystonia caused by antipsychotic drugs.  Neurology . 1982;  32 1335-1346
    CrossrefPubMedGoogle Scholar
  • 71 Keegan D L, Rajput A H. Drug induced dystonia tarda: treatment with L-dopa.  Dis Nerv Sys . 1973;  38 167-169
    PubMedGoogle Scholar
  • 72 Sethi K D, Hess D C, Harp R J. Prevalence of dystonia in veterans on chronic antipsychotic therapy.  Mov Disord . 1990;  5 319-321
    CrossrefPubMedGoogle Scholar
  • 73 Yassa R, Nair V, Dimitor R. Prevalence of tardive dystonia.  Acta Psychiatr Scand . 1986;  73 629-633
    PubMedGoogle Scholar
  • 74 Van Harten N P, Matroos G E, Hoek H W, Kahn R S. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia. The Curacao Extrapyramidal Syndromes Study: I.  Schizophr Res . 1996;  19 195-203
    CrossrefPubMedGoogle Scholar
  • 75 Kang U J, Burke R E, Fahn S. Natural history and treatment of tardive dystonia.  Mov Disord . 1986;  1 193-208
    CrossrefPubMedGoogle Scholar
  • 76 Kiriakakis V, Bhatia K, Quinn N P, Marsden C D. The natural history of tardive dystonia: a long term follow-up study of 107 cases.  Brain . 1998;  121 2053-2066
    CrossrefPubMedGoogle Scholar
  • 77 Wojick J D, Falk W E, Fink J S, Cole J O, Gelenberg A J. A review of 32 cases of tardive dystonia.  Am J Psychiatry . 1991;  148 1055-1059
    PubMedGoogle Scholar
  • 78 Sethi K D, Hess D C, Harmon D. Reverse obstructive sleep apnea syndrome.  Neurology . 1988;  312 (312)
    PubMedGoogle Scholar
  • 79 Sachdev P. Tardive and chronically recurrent oculogyric crises.  Mov Disord . 1993;  8 93-98
    CrossrefPubMedGoogle Scholar
  • 80 Bressman S B, de Leon D, Raymond D. Secondary dystonia and the DYTI gene.  Neurology . 1997;  48 1571-1577
    PubMedGoogle Scholar
  • 81 Tarsy D, Kaufman D, Sethi K D. An open-label study of botulinum toxin A for treatment of tardive dystonia.  Neuropharmacology . 1997;  20 90-93
    PubMedGoogle Scholar
  • 82 Wang Y, Turnbull I, Calne S, Stoessl A J, Calne D B. Pallidotomy for tardive dyskinesia.  Lancet . 1997;  349 777-778
    CrossrefPubMedGoogle Scholar
  • 83 Stahl S. Tardive Tourette syndrome in autistic patients after long term neuroleptic administration.  Am J Psychiatry . 1980;  137 1267-1269
    PubMedGoogle Scholar
  • 84 Muller J, Aminoff M J. Tourette like syndrome after long term neuroleptic drug treatment.  Br J Psychiatry . 1982;  141 191-193
    PubMedGoogle Scholar
  • 85 Bharucha K J, Sethi K D. Tardive tourettism after exposure to neuroleptic therapy.  Mov Disord . 1995;  10 791-793
    CrossrefPubMedGoogle Scholar
  • 86 Tominaga H, Fukuzako H, Izumi K. Tardive myoclonus.  Lancet . 1987;  1 322
    PubMedGoogle Scholar
  • 87 Little J T, Jankovic J. Tardive myoclonus.  Mov Disord . 1987;  2 307-311
    CrossrefPubMedGoogle Scholar
  • 88 Stacy M S, Jankovic J. Tardive tremor.  Mov Disord . 1992;  1 53-57
    PubMedGoogle Scholar
  • 89 Meltzer H Y. New drugs for the treatment of schizophrenia.  Schizophrenia . 1993;  16 365-385
    PubMedGoogle Scholar
  • 90 Lieberman J A, Saltz B L, Johns C A, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia.  Br J Psychiatry . 1991;  158 503-510
    PubMedGoogle Scholar
  • 91 Factor S A, Friedman J H. The emerging role of clozapine in the treatment of movement disorders.  Mov Disord . 1997;  12 483-496
    CrossrefPubMedGoogle Scholar
  • 92 Tollefson G D, Beasley Jr M C, Tamura R N, Tran P V, Potvin J H. Blind, controlled, long-term study of the comparative incidence of treatment emergent tardive dyskinesia with olanzapine or haloperidol.  Am J Psychiatry . 1997;  154 1248-1254
    PubMedGoogle Scholar
  • 93 Miller D D, Shafruddin M JA, Kathol R G. A case of clozapine induced neuroleptic malignant syndrome.  J Clin Psychiatry . 1991;  52 99-101
    PubMedGoogle Scholar
  • 94 Bak T H, Bauer M, Schaub R T, Hellweg R, Reischies F M. Myoclonus in patients treated with clozapine: a case series.  J Clin Psychiatry . 1995;  56 418-422
    PubMedGoogle Scholar
  • 95 Bharucha K J, Zamrini E, Evans D, Durrell D, Sethi K D. Clozapine-induced asterixis.  Neurology . 1996;  46 A262
    PubMedGoogle Scholar
  • 96 Smego R A, Durack D T. The neuroleptic malignant syndrome.  Arch Intern Med . 1982;  142 1183-1185
    CrossrefPubMedGoogle Scholar
  • 97 Friedman J H. Recognition and treatment of neuroleptic malignant syndrome.  Curr Opin Neurol Neurosurg . 1988;  1 310-311
    PubMedGoogle Scholar
  • 98 Burke R E, Fahn S, Mayeux R. Neuroleptic malignant syndrome caused by dopamine depleting agents in a patient with Huntington's disease.  Neurology . 1981;  31 1022-1026
    PubMedGoogle Scholar
  • 99 Friedman J H, Feinberg S S, Feldman R G. Neuroleptic malignant like syndrome due to levodopa therapy withdrawal.  JAMA . 1985;  254 2792-2795
    CrossrefPubMedGoogle Scholar
  • 100 Granato J E, Stern B J, Ringel A. Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine.  Ann Neurol . 1983;  14 89-90
    CrossrefPubMedGoogle Scholar
  • 101 Rodriguez M E, Luquin M R, Lera G. Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion.  Mov Disord . 1990;  5 170-172
    CrossrefPubMedGoogle Scholar
      >